Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies and Coping Strategies
10.19746/j.cnki.issn1009-2137.2025.06.042
- VernacularTitle:CAR-T细胞治疗血液系统肿瘤耐药的机制及应对策略
- Author:
Jun-Xia HE
1
;
Ya-Ming XI
Author Information
1. 兰州大学第一临床医学院
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T cells;
hematological malignancies;
mechanisms of resistance;
coping strategies
- From:
Journal of Experimental Hematology
2025;33(6):1820-1824
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor(CAR)T cell therapy has made a major breakthrough in the treatment of hematological malignancies.However,more and more studies have shown that factors such as T-cell exhaustion,tumor antigen modulation,immunosuppressive tumor microenvironment,and CAR-T cell dysfunction can lead to relapse and CAR-T cell resistence in hematologic malignancies.Developing dual-targeted CAR-T cells,exploring new immune targets,blocking CAR-T cell exhaustion,combining CAR-T cells with other therapies,implementing bridging therapies,and designing novel immunotherapies may be strategies to address CAR-T cell resistance.This article reviews the mechanisms of resistance to CAR-T cell therapy in hematological malignancies and the corresponding coping strategies.
